Mitomycin C (MMC), Anticancer and antibiotic agent (ab120797)
Key features and details
- Anticancer and antibiotic agent
- CAS Number: 50-07-7
- Purity: > 99%
Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Streptomyces sp.
Overview
-
Product name
Mitomycin C (MMC), Anticancer and antibiotic agent -
Description
Anticancer and antibiotic agent -
Alternative names
- MMC
-
Purity
> 99% -
CAS Number
50-07-7 -
Chemical structure
Properties
-
Chemical name
(1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione
-
Molecular weight
334.33 -
Molecular formula
C15H18N4O5 -
PubChem identifier
5746 -
Storage instructions
Store at +4°C. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM
-
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N -
Source
Streptomyces sp.
-
Research areas
Associated products
-
Alternative Versions
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120797 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
Notes |
---|
Functional Studies
Use at an assay dependent concentration. |
Images
-
2D chemical structure image of ab120797, Mitomycin C (MMC), Anticancer and antibiotic agent
-
Functional assays: Caspase 8 (active) FITC Staining Kit (ab65614)
Active caspase 8 in control Jurkat cells (10e6/mL) or cells treated for five hours with 10 ug/mL Cyclohexamide (CHX) (ab120093) or four hours with 25 ug/mL Mitomycin C (MitoC) (ab120797). Background signal subtracted, duplicates; +/- SD.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (4)
ab120797 has been referenced in 4 publications.
- Chiou AE et al. Fluorescent Silica Nanoparticles to Label Metastatic Tumor Cells in Mineralized Bone Microenvironments. Small 17:e2001432 (2021). PubMed: 32462807
- Ruggiano A et al. The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability. Cell Rep 37:110080 (2021). PubMed: 34879279
- Li J et al. A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma. Mol Med Rep 16:7105-7111 (2017). PubMed: 28901423
- Massee M et al. Type I and II Diabetic Adipose-Derived Stem Cells Respond In Vitro to Dehydrated Human Amnion/Chorion Membrane Allograft Treatment by Increasing Proliferation, Migration, and Altering Cytokine Secretion. Adv Wound Care (New Rochelle) 5:43-54 (2016). PubMed: 26862462